On Jan. 12, 2001, Corus Pharma was incorporated as a private venture-backed development stage biopharmaceutical company focused on the development and commercialization of novel applications and formulations to treat respiratory diseases.

In 2006, Gilead Sciences acquired Corus Pharma for $365 million. In 2010, the Food and Drug Administration (FDA) approved Cayston(R)(aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa.